BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 19844110)

  • 1. Volume therapy and cardiocircular function during hyperthermic intraperitoneal chemotherapy.
    Raue W; Tsilimparis N; Bloch A; Menenakos C; Hartmann J
    Eur Surg Res; 2009; 43(4):365-72. PubMed ID: 19844110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodynamic and cardiovascular problems during modified hyperthermic intraperitoneal perioperative chemotherapy.
    Rankovic VI; Masirevic VP; Pavlov MJ; Ceranic MS; Milenkovic MG; Simic AP; Kecmanovic DM
    Hepatogastroenterology; 2007 Mar; 54(74):364-6. PubMed ID: 17523275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.
    Vaira M; Cioppa T; DE Marco G; Bing C; D'Amico S; D'Alessandro M; Fiorentini G; DE Simone M
    In Vivo; 2009; 23(4):639-44. PubMed ID: 19567401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study.
    de Bree E; Rosing H; Filis D; Romanos J; Melisssourgaki M; Daskalakis M; Pilatou M; Sanidas E; Taflampas P; Kalbakis K; Beijnen JH; Tsiftsis DD
    Ann Surg Oncol; 2008 Apr; 15(4):1183-92. PubMed ID: 18239973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of gastric resections during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis.
    Piso P; Slowik P; Popp F; Dahlke MH; Glockzin G; Schlitt HJ
    Ann Surg Oncol; 2009 Aug; 16(8):2188-94. PubMed ID: 19408049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of the peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (IHPC): postoperative morbidity and mortality and short-term follow-up].
    Minicozzi A; Borzellino G; Momo EN; Segattini C; Pitoni F; Steccanella F; De Manzoni G
    Ann Ital Chir; 2008; 79(4):231-9. PubMed ID: 19093624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morbidity and mortality of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal carcinomatosis.
    Spiliotis J; Rogdakis A; Vaxevanidou A; Datsis A; Zacharis G; Christopoulou A
    J BUON; 2009; 14(2):259-64. PubMed ID: 19650176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Nonaka D; Langer M; Andreola S; Favaro M; Gavazzi C; Laterza B; Deraco M
    Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoreductive surgery associated to hyperthermic intraperitoneal chemoperfusion for desmoplastic round small cell tumor with peritoneal carcinomatosis in young patients.
    Msika S; Gruden E; Sarnacki S; Orbach D; Philippe-Chomette P; Castel B; Sabaté JM; Flamant Y; Kianmanesh R
    J Pediatr Surg; 2010 Aug; 45(8):1617-21. PubMed ID: 20713209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postoperative infections in cytoreductive surgery with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis.
    Capone A; Valle M; Proietti F; Federici O; Garofalo A; Petrosillo N
    J Surg Oncol; 2007 Nov; 96(6):507-13. PubMed ID: 17708508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.
    Verwaal VJ; van Ruth S; de Bree E; van Sloothen GW; van Tinteren H; Boot H; Zoetmulder FA
    J Clin Oncol; 2003 Oct; 21(20):3737-43. PubMed ID: 14551293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of peritoneal carcinomatosis with surgery and hyperthermic peroperative intraperitoneal chemotherapy (HIPEC): new aspects and validated indications].
    Eveno C; Dagois S; Guillot E; Gornet JM; Pocard M
    Bull Cancer; 2008 Jan; 95(1):141-5. PubMed ID: 18230580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis.
    Lim SJ; Cormier JN; Feig BW; Mansfield PF; Benjamin RS; Griffin JR; Chase JL; Pisters PW; Pollock RE; Hunt KK
    Ann Surg Oncol; 2007 Aug; 14(8):2309-18. PubMed ID: 17541691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Nonaka D; Oliva GD; Laterza B; Deraco M
    Ann Surg Oncol; 2007 Oct; 14(10):2790-7. PubMed ID: 17661150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study.
    Brigand C; Monneuse O; Mohamed F; Sayag-Beaujard AC; Isaac S; Gilly FN; Glehen O
    Ann Surg Oncol; 2006 Mar; 13(3):405-12. PubMed ID: 16485159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei.
    Witkamp AJ; de Bree E; Kaag MM; van Slooten GW; van Coevorden F; Zoetmulder FA
    Br J Surg; 2001 Mar; 88(3):458-63. PubMed ID: 11260116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Peritoneal carcinomatosis of colorectal cancer: cytoreductive surgery and hyperthermic intraperitoneal chemotherapy].
    Königsrainer I; Beckert S; Brücher B; Zieker D; Königsrainer A
    Dtsch Med Wochenschr; 2011 Sep; 136(36):1811-4. PubMed ID: 21882140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer.
    Roviello F; Pinto E; Corso G; Pedrazzani C; Caruso S; Filippeschi M; Petrioli R; Marsili S; Mazzei MA; Marrelli D
    J Surg Oncol; 2010 Nov; 102(6):663-70. PubMed ID: 20721959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center.
    Gusani NJ; Cho SW; Colovos C; Seo S; Franko J; Richard SD; Edwards RP; Brown CK; Holtzman MP; Zeh HJ; Bartlett DL
    Ann Surg Oncol; 2008 Mar; 15(3):754-63. PubMed ID: 18080166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of delayed hyperthermic intraperitoneal chemotherapy in case of unforeseen complications.
    Mohr Z; Hirche C; Liebeskind U; Rau B; Hünerbein M
    Eur Surg Res; 2011; 47(1):19-25. PubMed ID: 21540615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.